11C-PS13

DRUG3 trials

Sponsors

National Institute of Mental Health (NIMH)

Conditions

ALSAlzheimer's DiseaseDementiaLong COVIDMild Cognitive ImpairmentMultiple SclerosisParkinson's DiseasePost Acute Sequelae of COVID-19

Phase 1

PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease

RecruitingNCT04396873

National Institute of Mental Health (NIMH)ALS, Alzheimer's Disease, Dementia +2

Start: 2021-08-17End: 2030-10-03Target: 184Updated: 2026-02-17

PET Imaging of Cyclooxygenase-1 in Participants With Neurological Manifestations of Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)

RecruitingNCT06920628

National Institute of Mental Health (NIMH)Long COVID, Post Acute Sequelae of COVID-19

Start: 2025-06-18End: 2029-02-22Target: 60Updated: 2026-03-03

Phase 2

PET Imaging of Cyclooxygenase in Multiple Sclerosis

TerminatedNCT05062083

National Institute of Mental Health (NIMH)Multiple Sclerosis

Start: 2022-06-07End: 2024-01-30Updated: 2024-06-27